Researchers unveiled a chemiluminescent microfluidic chip with dielectric wetting valves that non‑invasively measures embryo metabolites to predict implantation potential. The device integrates precise fluid control with sensitive metabolic readouts to profile embryos without invasive biopsy, addressing a key bottleneck in IVF selection. The platform demonstrated predictive capability in experimental cohorts, proposing a route to refine embryo selection and potentially improve IVF success rates. The technology emphasizes low‑volume assays and compatibility with standard embryology workflows. Fertility clinics and reproductive‑tech companies should evaluate validation across larger, prospective clinical cohorts and regulatory pathways for diagnostic claims before adoption into routine practice.